Prema Muthusamy1, Krishnan Vengadaragava Chary2, G K Nalini3. 1. Postgraduate, Department of Pharmacology, Haasan Institute of Medical Sciences , Haasan, Karanataka, India . 2. Assistant Professor, Department of Pharmacology, Saveetha Medical College , Chennai, Tamil Nadu, India . 3. Professor, Department of Pharmacology, Haasan Institute of Medical Sciences , Haasan, Karanataka, India .
Abstract
INTRODUCTION: Metronomic chemotherapy is an emerging method of chemotherapy. Metronomic 'lowdose' chemotherapy regimen induces tumour dormancy and reduces cancer resistance against anticancer drugs. It tends to improve overall success rate of cancer chemotherapy than conventional cyclical regimen. AIM: The aim of this systemic review was to provide comprehensive data of metronomic chemotherapy trials, regimens used and it's outcome in cancer therapeutics. MATERIALS AND METHODS: Fifty chemotherapy trial data were searched sequentially from web. The main sources were official website of Clinical trial forum, USA and Clinical Trial Registry India (CTRI). Evidence on efficacy and safety of such metronomic chemotherapy trials was gathered from various data published in Medline, New England Journal of Medicine (NEJM), Lancet Oncology and other journals with high credentials. As a result of our search, out of 50 trials including breast -15(30%), colon-, 5(10%) ovarian -5(10%), prostate-5(10%) and others including haematologic, soft tissue and nervous system malignancies -20 (50%). Twenty seven trials showed favourable, 20 trials showed equivocal outcome and 3 trials reported unfavourable outcome. Overall comparison showed definitive statistical significance for using metronomic regimen (p-0.05). CONCLUSION: It can be concluded that metronomic chemotherapy regimen seems convincing beneficial to induce tumour remission and survival at a higher than conventional regimen. More metanalyses are needed to frame common metronomic chemotherapeutic regimen.
INTRODUCTION: Metronomic chemotherapy is an emerging method of chemotherapy. Metronomic 'lowdose' chemotherapy regimen induces tumour dormancy and reduces cancer resistance against anticancer drugs. It tends to improve overall success rate of cancer chemotherapy than conventional cyclical regimen. AIM: The aim of this systemic review was to provide comprehensive data of metronomic chemotherapy trials, regimens used and it's outcome in cancer therapeutics. MATERIALS AND METHODS: Fifty chemotherapy trial data were searched sequentially from web. The main sources were official website of Clinical trial forum, USA and Clinical Trial Registry India (CTRI). Evidence on efficacy and safety of such metronomic chemotherapy trials was gathered from various data published in Medline, New England Journal of Medicine (NEJM), Lancet Oncology and other journals with high credentials. As a result of our search, out of 50 trials including breast -15(30%), colon-, 5(10%) ovarian -5(10%), prostate-5(10%) and others including haematologic, soft tissue and nervous system malignancies -20 (50%). Twenty seven trials showed favourable, 20 trials showed equivocal outcome and 3 trials reported unfavourable outcome. Overall comparison showed definitive statistical significance for using metronomic regimen (p-0.05). CONCLUSION: It can be concluded that metronomic chemotherapy regimen seems convincing beneficial to induce tumour remission and survival at a higher than conventional regimen. More metanalyses are needed to frame common metronomic chemotherapeutic regimen.
Entities:
Keywords:
Cancer resistance; Low dose chemotherapy; Maintenance chemotherapy
Authors: Asa Jellvert; Ingela Franck Lissbrant; Maliha Edgren; Elisabeth Ovferholm; Karin Braide; Ann-Marie Ekelund Olvenmark; Jon Kindblom; Per Albertsson; Bo Lennernäs Journal: Exp Ther Med Date: 2011-05-12 Impact factor: 2.447
Authors: Xavier Elharrar; Dominique Barbolosi; Joseph Ciccolini; Christophe Meille; Christian Faivre; Bruno Lacarelle; Nicolas André; Fabrice Barlesi Journal: BMC Cancer Date: 2016-04-20 Impact factor: 4.430
Authors: Isabel Tena; Garima Gupta; Marcos Tajahuerce; Marta Benavent; Manuel Cifrián; Alejandro Falcon; María Fonfria; Maribel Del Olmo; Rosa Reboll; Antonio Conde; Francisca Moreno; Julia Balaguer; Adela Cañete; Rosana Palasí; Pilar Bello; Alfredo Marco; José Luis Ponce; Juan Francisco Merino; Antonio Llombart; Alfredo Sanchez; Karel Pacak Journal: Clin Med Insights Oncol Date: 2018-04-09